DERM News and Press, Journey Medical Corporation

2026-01-22 20:43:20 ET Most microcap biopharma stocks are binary bets. You either get a drug approval and a buyout or you get a failed trial and a zero. Journey Medical ( DERM ) is different, and I think the market is having a hard time categorising it. As opposed to a researc...

2026-01-05 16:15:00 ET Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval. However, the industry's major underlying drivers — higher rates of cancer and chronic di...

Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on skin, GI tract or vaginal microbiota FDA-approved Emrosi (40 mg Minocycline Hydroch...

2025-11-12 19:31:33 ET Journey Medical Corporation (DERM) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST... Read the full article on Seeking Alpha For further details see: Journey Medical Corporation (DERM) Q3 2025 Earnings Call Transcript

2025-11-12 17:29:04 ET More on Journey Medical Journey Medical: EMROSI's Ramp Puts Profitability On The Horizon Seeking Alpha’s Quant Rating on Journey Medical Historical earnings data for Journey Medical Financial information for Journey Medical ...

Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and...

RWE AG ADR (RWEOY) is expected to report $0.16 for Q3 2025 Hillenbrand Inc (HI) is expected to report $0.62 for Q4 2025 Ardent Health Inc. (ARDT) is expected to report $0.42 for Q3 2025 Quince Therapeutics Inc. (QNCX) is expected to report $-0.2 for Q3 2025 GlobalFoundries Inc. (G...

SCOTTSDALE, Ariz., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA...

FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults DFD-29 demonstrated superior efficacy in IGA success rates a...

SCOTTSDALE, Ariz., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA...